WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a…
88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual…
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema…
Register now to ask questions of researchers during the webinar CAPE CANAVERAL, Fla., Oct. 18, 2024 /PRNewswire/ -- The International…
The “Powering Milwaukee Forward” initiative will fund 10 Milwaukee organizations to increase access to basic needs and maternal healthcare in…
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or…
Presentation and live Q&A to take place Wednesday, October 23, 2024, at 12 PM EDTMarlborough, Massachusetts--(Newsfile Corp. - October 18,…
Dublin, Ireland--(Newsfile Corp. - October 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) shareholders today approved the…
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments…
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in…